

ASX/Media Release
2 September 2009

**PRIMA BIOMED SECURES SOUTH KOREAN PATENT FOR ONCOMAB
CANCER ANTIBODY TREATMENT**

Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that its subsidiary company, Oncomab Pty Ltd (Oncomab), has received Notification of Grant from the Republic of South Korea Patent Office for its cancer antibody antigen Cripto-1.

The new granted patent protects the use of a cancer antibody antigen, Cripto-1.

Cripto-1 is a protein found in high levels on the surface of many different kinds of cancer cells and is also found in the blood stream of cancer patients. The antibody works by binding to the Cripto-1 molecule and interfering with cell signalling, which results in the death of the cancer cell. The antibody may additionally be coupled to cytotoxic drugs to deliver an even more lethal combination of drug and cell signal to cancer cells.

Prima's Cripto-1 antibody was recently published in the highly regarded British Journal of Medicine.

The new Patent number is 0909290 and is titled, Antibodies against Cancer and expires in March 2021. Importantly, the patent has also been granted in Australia, New Zealand, China and the USA.

Prima executive director Martin Rogers said he was delighted with the grant of patent for Oncomab, which complements the recent success the Company has achieved with its core product, the **CVac™** ovarian cancer vaccine therapy treatment.

ENDS

For further information please contact:

Martin Rogers
Executive Director
Prima BioMed
Ph: 0428 268 357
E: martin.rogers@primabiomed.com.au
Website: www.primabiomed.com.au

James Moses
Investor and Media Relations
Mandate Corporate
Ph: 0420 991 574
E: james@mandatecorporate.com.au

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the **CVac™** ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.